|
|
조선살
|
|
 |
TwEOyGecsSd |
 |
387 |
|
 |
| Insufficient funds http://xxxx.in.net/ indo xxx Gilead's McHutchison said data on another of his company'sall-oral regimens - sofosbuvir combined with NS5A inhibitorledipasvir - will be presented at a medical meeting in April,and the company plans to file for FDA approval in the first halfof next year. |
|
 |
Wilfred |
 |
2019-09-08 01:18:07 |
|
|
|
|
|
|
|
|
|
